Imagenebio Stock Performance
| IMA Stock | 6.58 0.25 3.66% |
The company retains a Market Volatility (i.e., Beta) of 0.83, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, ImageneBio's returns are expected to increase less than the market. However, during the bear market, the loss of holding ImageneBio is expected to be smaller as well. At this point, ImageneBio has a negative expected return of -0.17%. Please make sure to check out ImageneBio's potential upside, day median price, and the relationship between the total risk alpha and accumulation distribution , to decide if ImageneBio performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days ImageneBio has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's primary indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
Actual Historical Performance (%)
One Day Return (3.66) | Five Day Return (4.78) | Year To Date Return (2.66) | Ten Year Return (98.29) | All Time Return (98.29) |
Last Split Factor 1:12 | Last Split Date 2025-07-28 |
1 | Insider Trading | 10/31/2025 |
2 | IMA Welcomes Six New Senior Fellows to Its Global Network Independent Doctors Continue to Grow in Influence Across Americas Healthcare Reform Landscape | 11/05/2025 |
3 | Wedbush Comments on ImageneBios Q4 Earnings - MarketBeat | 11/28/2025 |
4 | Acquisition by Slattery Joseph P of 31200 shares of ImageneBio at 6.19 subject to Rule 16b-3 | 12/18/2025 |
5 | Acquisition by Slattery Joseph P of 16000 shares of ImageneBio at 5.99 subject to Rule 16b-3 | 12/24/2025 |
6 | Top ImageneBio Insider Makes Bold New Move on Company Stock - TipRanks | 12/29/2025 |
7 | Acquisition by Erin Butler of 22500 shares of ImageneBio at 7.11 subject to Rule 16b-3 | 12/30/2025 |
8 | Joseph Slattery Spends US96k On ImageneBio Stock | 12/31/2025 |
9 | Accountants Enter 2026 Downbeat on Global Economic Prospects | 01/15/2026 |
| Begin Period Cash Flow | 121.2 M | |
| Total Cashflows From Investing Activities | -34.9 M |
ImageneBio | Build AI portfolio with ImageneBio Stock |
ImageneBio Relative Risk vs. Return Landscape
If you would invest 758.00 in ImageneBio on October 18, 2025 and sell it today you would lose (100.00) from holding ImageneBio or give up 13.19% of portfolio value over 90 days. ImageneBio is generating negative expected returns assuming volatility of 3.6698% on return distribution over 90 days investment horizon. In other words, 32% of stocks are less volatile than ImageneBio, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
ImageneBio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ImageneBio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ImageneBio, and traders can use it to determine the average amount a ImageneBio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0454
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IMA |
Based on monthly moving average ImageneBio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ImageneBio by adding ImageneBio to a well-diversified portfolio.
ImageneBio Fundamentals Growth
ImageneBio Stock prices reflect investors' perceptions of the future prospects and financial health of ImageneBio, and ImageneBio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ImageneBio Stock performance.
| Operating Margin | (5.01) % | ||||
| Current Valuation | 111.51 M | ||||
| Shares Outstanding | 11.18 M | ||||
| Price To Sales | 21.32 X | ||||
| Revenue | 3.5 M | ||||
| Gross Profit | 4.3 M | ||||
| EBITDA | (35.47 M) | ||||
| Net Income | (49.23 M) | ||||
| Total Debt | 7.52 M | ||||
| Book Value Per Share | (0.43) X | ||||
| Cash Flow From Operations | (46 M) | ||||
| Earnings Per Share | (4.33) X | ||||
| Market Capitalization | 91.69 M | ||||
| Total Asset | 141.51 M | ||||
| Retained Earnings | (331.62 M) | ||||
| Working Capital | (4.74 M) | ||||
About ImageneBio Performance
By analyzing ImageneBio's fundamental ratios, stakeholders can gain valuable insights into ImageneBio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if ImageneBio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ImageneBio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.23) | (0.24) | |
| Return On Capital Employed | (0.25) | (0.27) | |
| Return On Assets | (0.23) | (0.24) | |
| Return On Equity | (0.33) | (0.32) |
Things to note about ImageneBio performance evaluation
Checking the ongoing alerts about ImageneBio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ImageneBio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ImageneBio generated a negative expected return over the last 90 days | |
| ImageneBio has high historical volatility and very poor performance | |
| ImageneBio was previously known as IKNA Old and was traded on NASDAQ Exchange under the symbol IKNA. | |
| The company reported the last year's revenue of 3.5 M. Reported Net Loss for the year was (49.23 M) with profit before taxes, overhead, and interest of 4.3 M. | |
| ImageneBio generates negative cash flow from operations | |
| ImageneBio has a frail financial position based on the latest SEC disclosures | |
| About 14.0% of the company shares are held by company insiders | |
| Latest headline from globenewswire.com: Accountants Enter 2026 Downbeat on Global Economic Prospects |
- Analyzing ImageneBio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ImageneBio's stock is overvalued or undervalued compared to its peers.
- Examining ImageneBio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ImageneBio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ImageneBio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ImageneBio's stock. These opinions can provide insight into ImageneBio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for ImageneBio Stock analysis
When running ImageneBio's price analysis, check to measure ImageneBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImageneBio is operating at the current time. Most of ImageneBio's value examination focuses on studying past and present price action to predict the probability of ImageneBio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImageneBio's price. Additionally, you may evaluate how the addition of ImageneBio to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |